Table 1 Baseline characteristics of participants in each arm.
From: Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer
Characteristic | Ganitumab (n = 106) | Control (n = 128) |
|---|---|---|
Median age (range), yr | 48 (23–70) | 47.5 (24–77) |
Ethnicity, n (%) | ||
White | 86 (81%) | 101 (79%) |
African American | 12 (11%) | 18 (14%) |
Asian | 8 (8%) | 7 (5%) |
Other/Mixed | 0 (0%) | 2 (2%) |
HR Status, n (%) | ||
Positive | 58 (55%) | 66 (52%) |
Negative | 48 (45%) | 62 (48%) |
Mammaprint Status, n (%) | ||
MP.Hi1 | 47 (44%) | 70 (55%) |
MP.Hi2 | 59 (56%) | 58 (45%) |
Median Tumor Size by MRI (range), cm | 3.6 (0.8–14.7) | 3.9 (1.2–15) |
Baseline node status, n (%) | ||
Palpable | 26 (25%) | 60 (47%) |
Non-palpable | 67 (63%) | 59 (46%) |
N/A | 13 (12%) | 9 (7%) |
